MSB 0.91% $1.11 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-787

  1. 482 Posts.
    lightbulb Created with Sketch. 247
    I'm convinced Novartis is not pulling out now. It's clear to me their primary goal is obtaining GVHD with ARDS to follow. Why was GVHD an ad-on to the contract? Why were they given world wide rights to GVHD when the main contract was for all cause ARDS?

    They're not interested in C19 ARDS really, just a bonus. Same MOA for GVHD and ARDS

    No brainer.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.